Kamada to Supply Israel With Its Experimental COVID-19 Treatment

Photo: Reuters / Ronen Zvulun
>>Follow Matzav On Whatsapp!<<

Biopharmaceutical firm Kamada Ltd said on Monday it will supply Israel‘s Health Ministry with its experimental COVID-19 treatment for 500 patients in Israel.

Use of the “investigational” plasma-derived immunoglobulin product will be regulated by the ministry, the Israeli company said.

Kamada will manufacture the product from convalescent plasma collected by the Israeli National Blood Services and additional Israeli medical institutions.

The initial order, planned to be supplied during the beginning of 2021, is sufficient to treat some 500 hospitalized patients. This initial supply is expected to generate $3.4 million in revenue for Kamada in the first quarter of 2021.

Kamada said interim results of an ongoing Phase 1/2 clinical trial in Israel showed its product had a favorable safety profile and symptoms improvement was observed in hospitalized, non-ventilated COVID-19 patients with pneumonia.

“We will continue to ramp up the production and supply of the product during the next few months,” Kamada CEO Amir London said.

Algemeiner Staff. (c) 2020.



  1. “Its Experimental COVID-19 Treatment” Now you understand why the third leading cause of deaths heart disease and cancer is medical malpractice. Their motto goes, ‘so what another person is a guinea pig, as long as it’s not my family.’ The Chevra Kadisha are so right for saying they have less work when hospitals are on strike and they said that the since the hospital massacre stopped after Pesach, they b”H don’t have much work.

    Why do they need experimental treatment when 99% are cured with hydroxychloroquine? And they know it well because they’ve been using it for decades for cancer, although they didn’t want the public to know about it.


Please enter your comment!
Please enter your name here